Loading clinical trials...

NOT_YET_RECRUITING

Long-term Survival and Influencing Factors of Patients With Pulmonary Arterial Hypertension and Diabetes

Long-term Survival and Influencing Factors of Patients With Pulmonary Arterial Hypertension and diabetes-a Multicenter Retrospective Cohort Study

NCT07082933•Xijing Hospital

View on ClinicalTrials.gov

Summary

This is a multicenter retrospective cohort study on pulmonary arterial hypertension. It is expected to collect data from no less than 5,000 patients to compare the long-term overall survival of patients with and without diabetes, and analysis the risk factors of the overall survival .

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Individuals aged 18 to 80 years with full capacity for civil conduct.
•Patients diagnosed with pulmonary hypertension by community-level and/or higher-level medical institutions.

Exclusion Criteria

•Patients with malignant tumors.
•Other physical conditions judged by the researchers as making the patients ineligible to participate in the clinical study.

Key Dates

Start Date

August 1, 2025

Primary Completion Date

August 1, 2027

Completion Date

December 31, 2027

Last Updated

July 24, 2025

Enrollment

5,000

ESTIMATED participants

Conditions

Pulmonary Arterial Hypertension (PAH)

Interventions

Standard medical treatment

OTHER

Contacts

Yue Zhang, Doctor

CONTACT

0086+13022957751 zhangy718@foxmail.com

COMPERA / COMPERA-KIDS

NCT01347216

Pulmonary Arterial Hypertension (PAH)Pulmonary Hypertension (PH)

View study

NOT_YET_RECRUITING

What is the Role of the Exposome in Pulmonary Hypertension

NCT07172334

Pulmonary Arterial Hypertension (PAH)Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 24, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Long-term Survival and Influencing Factors of Patients With Pulmonary Arterial Hypertension and Diabetes

Inclusion Criteria

Exclusion Criteria

COMPERA / COMPERA-KIDS

What is the Role of the Exposome in Pulmonary Hypertension

SIRIUS - Initial Combination Therapy With an Endothelin Receptor Antagonist, a Phosphodiesterase-5 Inhibitor and Sotatercept in Patients With Newly Diagnosed Pulmonary Arterial Hypertension

The Effect of Slow-Paced Breathing on Patient Outcomes in Pulmonary Arterial Hypertension

Bioequivalence Study to Compare Selexipag 400mcg Film Coated Tablets (400 mcg Selexipag) Versus Uptravi® 400mcg Film Coated Tablets (400 mcg Selexipag)

(RIGHT HEART III Study - Right Ventricular Hemodynamic Evaluation and Response to Treatment)